LanzollaG, MaglionicoMN, ComiS, et al.Sirolimus as a second-line treatment for Graves’ orbitopathy. J Endocrinol Invest, 2022; 45(11):2171–2180; doi: 10.1007/s40618-022-01862-y
2.
ComiS, CosentinoG, LanzollaG, et al.Long-term outcome of Graves’ orbitopathy following treatment with sirolimus. J Endocrinol Invest, 2025; 48(3):607–618; doi: 10.1007/s40618-024-02470-8
3.
BartalenaL, KahalyGJ, BaldeschiL, et al.; EUGOGO. The 2021 European group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol, 2021; 185(4):G43–G67; doi: 10.1530/EJE-21-0479
4.
CosentinoG, LanzollaG, ComiS, et al.Ablative versus conservative approach for hyperthyroidism treatment in patients with Graves’ orbitopathy: A retrospective cohort study. Thyroid, 2025; 35(3):298–306; doi: 10.1089/thy.2024.0633
